

For the acute treatment of migraine in adults

one migraine.

one dose.<sup>1</sup>

onederful™

Actual Rimegepant Patient

Limitations of Use

Nurtec ODT is not indicated for the preventive treatment of migraine.

**SELECT IMPORTANT SAFETY INFORMATION**

**Contraindications:** Hypersensitivity to Nurtec ODT or any of its components.

**Please see additional Important Safety Information on the back and the accompanying full Prescribing Information located in the back pocket.**

**Nurtec™ ODT**  
(rimegepant)  
orally disintegrating tablets 75 mg



## Nurtec ODT. Different in WHAT it does.<sup>1</sup>

Just one quick-dissolving dose can<sup>1</sup>:



eliminate migraine pain



return patients to normal function

## Different in HOW it does it.<sup>1</sup>



**fast**

Quick-dissolve ODT can start working in minutes.<sup>1</sup>



**lasts**

Can work for up to 48 hours after just one dose.<sup>1,2</sup>



**simple**

One Dose. Anytime. Anywhere.<sup>1,\*</sup>

In a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), co-primary endpoints at 2 h for Nurtec ODT vs placebo were: pain freedom (21% vs 11%,  $p<0.001$ ) and freedom from most bothersome symptom (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%,  $p=0.001$ ). Select secondary endpoints at 60 minutes for Nurtec ODT vs placebo: pain relief (37% vs 31%,  $p<0.05$ ) and freedom from functional disability (22% vs 16%,  $p=0.0025$ ); from 2-48 h for Nurtec ODT vs placebo: pain freedom (14% vs 5%,  $p<0.001$ ), freedom from functional disability (26% vs 15%,  $p<0.0001$ ), and pain relief (42% vs 25%,  $p<0.001$ ).<sup>1,2</sup>

## The first and only quick-dissolve CGRP receptor antagonist.<sup>1,2</sup>

- 86% of patients did not take a rescue medication (including OTCs) within 24 hours post dose<sup>1,†</sup>
- Well tolerated with low rates of AEs<sup>1,2,‡</sup>
- Studied in patients taking preventive medication for migraine<sup>1</sup>
- Can be co-administered with oral contraceptives and antidepressants<sup>1</sup>
- Nurtec ODT Savings Program allows for eligible patients to pay as little as \$0 per month<sup>§</sup>

\*Nurtec ODT can be taken as needed up to once daily.<sup>1</sup>

†Rescue medication: NSAIDs, acetaminophen and/or antiemetic.<sup>1</sup>

‡AE experienced: nausea (Nurtec ODT 2% vs placebo 0.4%).<sup>1</sup>

§Per 8-tablet prescription. See Terms & Conditions at [Nurtec-HCP.com/savings-support](http://Nurtec-HCP.com/savings-support)

Find out more at [Nurtec-HCP.com](http://Nurtec-HCP.com)

### IMPORTANT SAFETY INFORMATION

**Contraindications:** Hypersensitivity to Nurtec ODT or any of its components.

**Warnings and Precautions:** If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

**Adverse Reactions:** The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

**Drug Interactions:** Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A4 or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

**Use in Specific Populations:** *Pregnant/breast feeding:* It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

### INDICATION

Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.

#### Limitations of Use

Nurtec ODT is not indicated for the preventive treatment of migraine.

Please see accompanying full Prescribing Information located in the back pocket.

Price disclosure information for prescribers available here: [Nurtec-HCP.com/pricing](http://Nurtec-HCP.com/pricing)

#### REFERENCES:

1. Nurtec ODT [Package Insert]. New Haven, CT: Biohaven Pharmaceuticals, Inc. 2. Croop R et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet*. 2019;394(10200):737-745.



**Nurtec™ ODT**  
(rimegepant)  
orally disintegrating tablets 75 mg

© 2020 Biohaven Pharmaceuticals, Inc. All rights reserved. Nurtec is a trademark or registered trademark of Biohaven Pharmaceuticals, Inc. BIOHAVEN and the Biohaven logo are trademarks or registered trademarks of Biohaven Pharmaceuticals, Inc. US-RIMODT-2000009 03/20